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in communities with a low TB prevalence and a high standard of
public health. Twenty-three consecutive adult MDR TB patients
who were treated at our institution between 2007 and 2013 were
reviewed for demographic characteristics and anti-TB treatment
management, which included surgical procedures and long-term
patient follow-up. This report of our experience emphasizes the
need for an individualized approach as MDR TB brings
mycobacterial disease management to a higher level of expertise,
and for a balance to be found between international current
guidelines and patient-tailored treatment strategies.
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VanhemsIntroductionThe emergence of multidrug-resistant (MDR) tuberculosis (TB)
is a major concern. In 2014, MDR TB represented 5% of all TB
cases [1]. Eastern European and Central Asian countries have
the highest levels of MDR TB (35% of new cases and 75% of
previously TB treated cases, respectively) [1]. Reports of pa-
tients with extensive drug-resistant TB are regularly referred to
[2]. The MDR TB cure rate ranges from 44% to 83%, and pa-
tients with MDR TB have a higher death rate (10–14%) than
those with susceptible TB [3]. Although France is among the
western Europe countries with the lowest prevalence of MDR
TB, its incidence has dramatically increased [4]. Assessing the
strengths and weaknesses of our institutional practices is of
critical importance to optimally confront this growing
challenge.MethodsWe performed a retrospective analysis of all consecutively
documented MDR TB adult cases patients who were treated at
our institution between 2007 and 2013. A standardized tem-
plate survey adapted from Sotgiu et al. [5], covering key TB
items, was used to collect patient data, which included socio-Diseases. Published by Elsevier Ltd. All rights reserved
CMI Catho et al. Management of emerging multidrug-resistant tuberculosis 472.e8demographic characteristics, clinical presentation, phenotypic
drug susceptibility testing (DST) for all anti-TB drugs [6], strain
genotyping as previously described [7,8], drug efﬁcacy and
tolerance, treatment outcome, surgical procedure, and long-
term patient follow-up.Results and discussionTwenty-three patients with documented MDR TB were
included. The male/female sex ratio was 2.8, and the mean age
was 32 years. Twenty-one (91%) patients were foreign-born (2/
3 from eastern Europe or Central Asia). Eighteen (78%) pa-
tients had not mastered any elementary language skill of the
host country, and two-thirds of them received shelter from
homeless public facilities. All patients but one (lymph node TB)
had pulmonary MDR TB with clinical presentations of chronic
cough (72%), weight loss (64%), fever (36%), and haemoptysis
(28%). Four (17%) patients had hepatitis C virus or hepatitis B
virus co-infection, and none had human immunodeﬁciency virus
co-infection. Regarding TB medical history, eight (35%) patients
had received prior curative anti-TB treatment, with unknown
combinations for six (75%) of the patients.
Sixteen (70%) strains belonged to the East Asian Beijing ge-
notype, and the Beijing genotype accounted for 7–11% in the
susceptible TB cohort during the same period [9]. Studies
suggest selective advantages of the Beijing genotype over other
lineages, more likely to induce cavitary disease and a high
sputum mycobacterial load [10,11].
Regarding DST, high resistance levels were observed for
ethionamide, ethambutol, pyrazinamide, and cycloserine (78%,TABLE 1. Use of individual anti-tuberculosis (TB) drugs with respec
mean treatment duration in 23 multidrug-resistant TB patients
Drug use
Group I Group II Group III Gr
EMB PZA AMK FQ ET
Overall, n (%) 12 (48) 11 (44) 20 (87) 21 (91) 12
Part of the ﬁrst
combination, n (%)
12 (100) 11 (100) 18 (90) 21 (100) 11
Part of the second
combination, n (%)
– – 1 (5) – 1 (
Part of the third
combination, n (%)
– – 1 (5) – –
Median number of
drug changes (range)
3.24 (2–6)
Resistance-related drug
interruption, n (%)
6 (50) 2 (18) 1 (5) 2 (9,5) 6 (
Side effect-related drug
interruption, n (%)
0 (0) 1 (9) 7 (35) 0 (0) 1 (
Drug use mean duration
in days (range)
369 (15–671) 470 (76–671) 113 (30–244) 372 (33–701) 29
AMK, amikacin; AMX + CLAV, amoxycillin–clavulanate; BDQ, bedaquiline; CBP, carbapenem
later-generation ﬂuoroquinolones (moxiﬂoxacin or levoﬂoxacin); LNZ, linezolid; PAS, p-ami
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inf70%, 56%, and 30%, respectively), resulting in drug interruption
upon DST results. The resistance levels for amikacin, the later-
generation ﬂuoroquinolones moxiﬂoxacin and levoﬂoxacin, p-
aminosalicylic acid and linezolid were <20% or null. The anti-
biotic regimen choices and completion followed the WHO
guidelines [12]. The median treatment duration needed to
obtain negative sputum conversion was 50.5 ± 35.8 days.
Amikacin and ﬂuoroquinolones were used in 87% and 91% of
the cases, respectively (Table 1). The amikacin mean treatment
duration, which barely exceeded 3 months, was the second
shortest of all anti-TB drugs. Particular attention was given to
amikacin-related hearing loss for incoming migrants who were
in the process of learning a new language. Of 20 amikacin-
treated patients, six (30%) developed audiogram-conﬁrmed
hearing loss (>20-dB loss at any tested frequency) that
required drug interruption (Table 2) [13]. In the case of mod-
erate renal function impairment, the dose adjustment was
tested (increasing the dose interval to 48 h or lowering the daily
dose from 15 to 10 mg/kg/day), which allowed three patients to
receive further treatment. Overall, only three patients achieved
amikacin maintenance during the entire 8-month intensive
phase (Fig. 1). p-Aminosalicylic acid and linezolid were used in
83% and 78% of the cases, respectively (Table 1). Of 19 p-
aminosalicylic acid-treated patients, nine (47%) developed
nausea and vomiting, requiring drug interruption for eight pa-
tients (Table 2). A high ethionamide resistance rate (78%)
resulted in a shift to linezolid, because recent studies have
conﬁrmed that linezolid is an effective MDR TB drug [14]. For
the 18 linezolid-treated patients, lowering the daily dose from
1200 mg to 600 mg undoubtedly improved long-term linezolid
tolerability, despite two (11%) interruptions for cytopenia andt to timing and optimization of use, cause of interruption and
oup IV Group V
O CS PAS LNZ BDQ
CBP +
AMX +
CLAV
(48) 15 (65) 19 (83) 18 (78) 10 (43) 2 (8)
(92) 13 (87) 15 (79) 12 (67) 2 (20) 1 (50)
8) 2 (13) 1 (5) 4 (22) 6 (60) 1 (50)
1 (7) 3 (16) 2 (11) 2 (20) –
50) 2 (13) 1 (5) 0 (0) 0 (0) 1 (50)
8) 1 (7) 9 (47) 8 (44,5) 0 (0) 0 (0)
6 (15–671) 299 (21–701) 207 (9–518) 229 (30–701) 181 (170–186) 100
(imipenem or meropenem); CS, cycloserin; EMB, ethambutol; ETO, ethionamide; FQ,
nosalicylic acid; PZA, pyrazinamide.
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TABLE 2. Drug-related adverse events and subsequent requirement for dosage adjustment or drug interruption in 23 multidrug-
resistant tuberculosis patients
Adverse events n Drug-related
Event requiring
dosage adjustment, n (%)
Event requiring drug interruption
for >5 days, n (%)
Hearing loss 6 AMK — 6 (100)
Nephrotoxicity 4 AMK 3 (75) 1 (25)
Gastritis, nausea, vomiting 9 PAS — 8 (89)
Psychiatric effects 2 CS 1 (50) 1 (50)
Hypothyroidism 3 ETO, PAS, CS — 1 (33)
Joint/musculoskeletal pain 5 FQ — —
Neuropathy (peripheral and optic) 7 LNZ — 6 (86)
Cytopenia (anaemia, thrombopenia) 8 LNZ 6 (75) 2 (25)
Hepatitis 3 PZA — 1 (33)
AMK, amikacin; CS, cycloserin; ETO, ethionamide; FQ, later-generation ﬂuoroquinolones (moxiﬂoxacin or levoﬂoxacin); LNZ, linezolid; PAS, p-aminosalicylic acid; PZA,
pyrazinamide.
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(Table 2). The novelty was the use of a 24-week regimen of the
diarylquinoline anti-TB drug bedaquiline for ten (43%) patients.
In placebo-controlled studies, adding bedaquiline to standard
therapy for MDR TB reduced the time to conversion and
increased the proportion of patients with negative sputum
conversion [15,16]. Minor clinically relevant side effects, pri-
marily nausea, were reported. No changes in heart rate or
electrocardiographic QRS or PR intervals were observed when
bedaquiline was combined with ﬂuoroquinolones. Although
caution is recommended until upcoming phase III trial results
are available, bedaquiline is expected to replace the most toxic
drugs and to contribute to shortening MDR TB treatment [17].
Sixteen (70%) patients had cavitary lesions involving one or
more pulmonary lobes. Previous studies support an improved
outcome when both surgical resection and an optimized drug
combination are used [18]. The surgical resection of cavitary
lesions or destroyed lungs was individually considered for sevenClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectpatients upon negative sputum conversion that was deemed to
fail medical treatment (complex resistance patterns and/or the
extent of the disease). Six patients agreed to surgery. The mean
treatment duration before surgery was 6.6 months (range,
3–15 months), which was a rather short delay considering that
our primary goal was a decrease in mycobacterial burden to
improve the treatment outcome. Immediate postoperative
complications were prolonged air leakage through bronchial
sutures and mild bleeding for two patients.
Previously published consensus deﬁnitions for treatment
outcome were used [19]. In our series, the median duration of
follow-up was 30 ± 8.2 months. Eighteen (78%) patients
completed the treatment, with no attributable related mortality
and relapse-free cure thus far. Three patients defaulted, and
two patients remain in the continuation phase, with three active
anti-TB drugs (Fig. 1). Notably, only nine (39%) patients could
be isolated in the single negative-pressure ventilation room of
our facility from the time of admission until sputum conversion.FIG. 1. Summary of multidrug-resistant
(MDR) tuberculosis (TB) patients who ach-
ieved intensive and continuation phases with
the recommended number of drugs, and the
current status of ongoing treatments (the
intensive phase lasted for 8 months, and the
continuation phase lasted for 12 months).
AMK, amikacin.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 472.e7–472.e10
CMI Catho et al. Management of emerging multidrug-resistant tuberculosis 472.e10MDR TB treatment faces the difﬁculties of individually
tailoring the most appropriate treatment strategy and
combining efﬁcacy, safety, and tolerability.
Transparency declarationThe authors declare that they have no conﬂicts of interest.
AcknowledgementsThe authors gratefully acknowledge C. Bernard, J. Robert and
V. Jarlier from the French National Reference Centre for
Mycobacteria.
References[1] World Health Organization. Global tuberculosis report 2014. Geneva:
World Health Organization; 2014.
[2] Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant
tuberculosis in India. Clin Infect Dis 2012;54:579–81.
[3] Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment
outcomes of multidrug-resistant tuberculosis: a systematic review and
meta-analysis. PLoS One 2009;4:e6914.
[4] Bernard C, Brossier C, Sougakoff W, Veziris N, Frechet-Jachym M,
Metivier N, et al. A surge of MDR and XDR tuberculosis in France
among patients born in the former Soviet Union. Euro Surveill
2013;18:20555.
[5] Sotgiu G, Centis R, D’Ambrosio L, et al. Development of a stand-
ardised tool to survey MDR-/XDR-TB case management in Europe.
Eur Respir J 2010;36:208–11.
[6] World Health Organization. Policy guidance on drug-susceptibility
testing (DST) of second-line antituberculosis drugs. Geneva: WHO;
2008.
[7] Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D,
Kuijper S, et al. Simultaneous detection and strain differentiation ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfMycobacterium tuberculosis for diagnosis and epidemiology. J Clin
Microbiol 1997;35:907–14.
[8] Vitol I, Driscoll J, Kreiswirth B, Kurepina N, Bennett KP. Identifying
Mycobacterium tuberculosis complex strain families using spoligotypes.
Infect Genet Evol 2006:451–504.
[9] Langlois-Klassen D, Kunimoto D, Saunders LD, Chui L, Boffa J,
Menzies D, et al. A population-based cohort study of Mycobacterium
tuberculosis Beijing strains: an emerging public health threat in an
immigrant-receiving country? PLoS One 2012;7:e38431.
[10] López B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, et al.
A marked difference in pathogenesis and immune response induced by
different Mycobacterium tuberculosis genotypes. Clin Exp Immunol
2003;133:30–7.
[11] Parwati I, van Crevel R, van Soolingen D. Possible underlying mecha-
nisms for successful emergence of the Mycobacterium tuberculosis Bei-
jing genotype strains. Lancet Infect Dis 2010;10:103–11.
[12] Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J,
et al. WHO guidelines for the programmatic management of drug-
resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516–28.
[13] Sturdy A, Goodman A, José RJ, Loyse A, O’Donoghue M, Kon OM,
et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK:
a study of injectable use and toxicity in practice. J Antimicrob Che-
mother 2011;66:1815–20.
[14] Sotgiu G, Centis R, D’Ambrosio L, Alffenaar JW, Anger HA,
Caminero JA, et al. Efﬁcacy, safety and tolerability of linezolid con-
taining regimens in treating MDR-TB and XDR-TB: systematic review
and meta-analysis. Eur Respir J 2012;40:1430–42.
[15] Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-
Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant
tuberculosis. N Engl J Med 2009;360:2397–405.
[16] Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E,
Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conver-
sion with Bedaquiline. N Engl J Med 2014;371:723–32.
[17] Cohen J. Infectious disease. Approval of novel TB drug celebrated—
with restraint. Science 2013;339(6116):130.
[18] Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA,
Mase SR. Surgical interventions for drug-resistant tuberculosis: a sys-
tematic review and meta-analysis. Int J Tuberc Lung Dis 2013;17:6–16.
[19] Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD,
Riekstina V, et al. Speaking the same language: Treatment outcome
deﬁnitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis
2005;9:640–5.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 472.e7–472.e10
